| Product Name | LBP ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Lipopolysaccharide Binding Protein (LBP). No significant cross-reactivity or interference between Lipopolysaccharide Binding Protein (LBP) and analogues was observed. |
| Synonyms | LPS-Binding Protein |
| Method | Sandwich |
| Detection Range | 3.12-200ng/mL |
| Sensitivity | 1.21ng/mL |
| Target | LBP |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Lipopolysaccharide Binding Protein (LBP). No significant cross-reactivity or interference between Lipopolysaccharide Binding Protein (LBP) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P18428 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | A Marker of Endotoxemia Is Associated With Obesity and Related Metabolic Disorders in Apparently Healthy Chinese;Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy;Gut microbiome composition is linked to whole grain-induced immunological improvements;The effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patients;A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome.;Frequency and Severity of Cirrhotic Cardiomyopathy and Its Possible Relationship with Bacterial Endotoxemia;Circulating pathogen associated molecular pattern – Binding proteins and High Mobility Group Box protein 1 in nascent metabolic syndrome: Implications for cellular Toll-like receptor activity;Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study;Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis;High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis;A standardized extract of the fruit of Hovenia dulcis alleviated alcohol-induced hangover in healthy subjects with heterozygous ALDH2: A randomized, controlled, crossover trial.;Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic …;High-dose Glycerol Monolaurate Up-Regulated Beneficial Indigenous Microbiota without Inducing Metabolic Dysfunction and Systemic Inflammation: New Insights …;Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study;Monocyte transcriptomes from patients with axial spondyloarthritis reveal dysregulated monocytopoiesis and a distinct inflammatory imprint;Composition and Functions of the Gut Microbiome in Pediatric Obesity: Relationships with Markers of Insulin Resistance;Elucidating the role of the gut microbiota in the physiological effects of dietary fiber;Сorrelation between the level of 25 (OH) D3 in blood, the content of antimicrobial peptides in oral fluid and dental caries intensity in young individuals; |
| Supplier | Cloud Clone |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.